Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCN9A | Q15858 | 20/20 | 0.64 |
| ▸ | CYP2C9 | P11712 | 3/20 | 0.64 |
| ▸ | SCN5A | Q14524 | 3/20 | 0.64 |
| ▸ | SCN2B | O60939 | 1/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN4A | P35499 | 1/20 | 0.51 |
| ▸ | SCN7A | Q01118 | 1/20 | 0.51 |
| ▸ | SCN1B | Q07699 | 1/20 | 0.51 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | SCN3A | Q9NY46 | 1/20 | 0.51 |
| ▸ | SCN8A | Q9UQD0 | 1/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1094748 | 0.91 | SCN9A (0.78) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL31643102 | 0.91 | SCN9A (0.78) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL1109038 | 0.84 | SCN9A (0.64) | SCN9ACYP2C9SCN5ASCN1ASCN2A | |
| Pf-05089771 SCHEMBL25819004 | 0.80 | SCN9A (0.77) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL319734 | 0.80 | SCN9A (0.65) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| Hydrochloric Acid SCHEMBL14889660 | 0.79 | SCN9A (0.64) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL17450366 | 0.78 | SCN9A (1.00) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| SCHEMBL16001939 | 0.77 | SCN9A (0.72) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| Pf-05089771 SCHEMBL21968007 | 0.76 | SCN9A (0.65) | SCN9ACYP2C9SCN5ASCN2BSCN1A | |
| Pf-05089771 SCHEMBL30543444 | 0.76 | SCN9A (0.65) | SCN9ACYP2C9SCN5ASCN2BSCN1A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8153814-B2 | Sulfonamide derivatives | PFIZER LIMITED (GB) | 2012-04-10 | — | — | US | disclosed |
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | Pfizer Limited Icagen, Inc. | 2010-08-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100197655-A1 | SULFONAMIDE DERIVATIVES | SULT2A1, SULT1A1, TPST2 | SCN9A 73/4885CYP2C9 75/4885SCN5A 19/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.